Celon Pharma (WAR:CLN) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:CLN Celon Pharma SA WAR:CLN
44 GF Score
Price zł21.10
GF Value zł23.72
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Celon Pharma FFO per Share?

FFO per Share only applies to REITs.

WAR:CLN
44GF Score
Celon Pharma SA WAR:CLN
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Celon Pharma (WAR:CLN) Overvalued in 2026?

Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued. The current stock price of zł21.10 is trading 11% below its estimated GF Value™ of zł23.72. GuruFocus considers Celon Pharma to be Modestly Undervalued.

Key valuation signals for WAR:CLN:

  • FFO per Share:
  • GF Value™: zł23.72 vs. price of zł21.10 (11% below fair value)
  • GF Score™: 44/100 with 3 warning signs

No single metric tells the full story. See the WAR:CLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celon Pharma Business Description

Other Exchanges 8RP:Germany
Address Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
44GF Score

Get the complete analysis for WAR:CLN

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł21.10
Price
zł23.72
GF Value